陈建忠，博士，浙江大学药学院教授，博导。1990年7月毕业于原杭州大学化学系（现浙江大学化学系），获理学学士学位，同年9月进入中国科学院上海药物研究所攻读研究生学位，分别于1993年和1996年获得有机化学理学硕士和理学博士学位，并留所担任助理研究员从事科研工作。作为主要研究人员之一于1997年获得中国科学院自然科学二等奖。1998年7月赴美国University of Connecticut药学院从事新药研发的基础性科研工作，并于2005年8月获得药学专业哲学博士学位。之后，继续分别在University of Houston药学院和University of Pittsburg药学院博士后研究。2008年9月回国任浙江大学药学院教授，博士生导师，主要开展药物设计和先导化合物发现的科学研究,以及药物代谢分子机制的理论研究。获得包括国家自然科学基金，十一·五国家新药创制重大专项关键技术项目，浙江省钱江人才计划，浙江省自然科学基金重点项目等科研项目资助。在包括PNAS，J. Biol. Chem., J. Med. Chem., ACS Med. Chem. Lett., Eur. J. Med. Chem., J. Phys. Chem., Proteins，Int. J. Pharmaceu.，J. Chem. Info. Model., Curr. Med. Chem., Mol. BioSys., Mol. Diver.等学术期刊上发表60余篇学术论文，以及近10项国际专利和中国专利申请或授权。

药物化学，药物设计，先导化合物优化和构效关系

1. H.-Y. Qian, Z.-L. Wang, Y.-L. Pan, L.-L. Chen, X. Xie*, J.-Z. Chen*. Development of Quinazoline/Pyrimidine-2,4(1H,3H)‑diones as Agonists of Cannabinoid Receptor Type 2. ACS Med. Chem. Lett. 2017, 8, 678–681 2. H.-Y. Qian, Z.-L. Wang, X.-Y. Xie, Y.-L. Pan, G.-J. Li, X. Xie*, J.-Z. Chen*. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies. Eur. J. Med. Chem. 2017, 137, 598-611. 3. H.-Y. Qian, S.-F. Chen,Y.-L. Pan, J.-Z. Chen*. Understanding the relative affinity and specificity of the substrate binding site of protein kinase B for substrate-mimetic inhibitors. Mol. Simulat. 2017, 17, 1459-1471 4. H. Qian, J. Chen, Y. Pan, J.-Z Chen*. Molecular Modeling Studies of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors through Receptor-Based 3D-QSAR and Molecular Dynamics Simulations，Molecules，2016, 21, 1222. 5. T. A. Chohan, J.-J. Chen, H.-Y. Qian，Y.-L. Pan，J.-Z. Chen*. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations，Mol. BioSyst., 2016, 12, 1250~1268 6. T. A. Chohan，H.-Y. Qian，Y.-L. Pan，J.-Z. Chen*. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)- pyrimidines in complexes with CDK2 and CDK7，Mol. Biosyst.，2016, 12, 145~161. 7. S. Han, F.-F. Zhang, H.-Y. Qian，L.-L. Chen，J.-B. Pu，X. Xie*, J.-Z. Chen*. Development of quinoline-2,4(1H,3H)-diones as potent and selectiveligands of the cannabinoid type 2 receptor，J. Med. Chem., 2015, 58, 5751~5769 8. S. Han, F.-F. Zhang, H.-Y., L.-L. Chen, X. Xie*, J.-Z. Chen*. Design, Syntheses, Structure-Activity Relationships and Docking Studies of Coumarin Derivatives as Novel Selective Ligands for the CB2 Receptor. Eur. J. Med. Chem, 2015, 93, 16-32. 9. T. A. Chohan, H. Qian, Y. Pan, J.-Z. Chen*. Cyclin-dependent kinase-2 as a target for cancer therapy: Progress in the development of CDK2 inhibitors as anti-cancer agents. Curr. Med. Chem. 2015, 22, 237-263 10. Y. Cao, S. Han, L. Yu, H. Qian, J.-Z. Chen*. MD and QM/MM Studies on Long-Chain L‑α-Hydroxy Acid Oxidase: Substrate Binding Features and Oxidation Mechanism. J. Phys. Chem. B 2014, 118, 5406-5417. 11. S. Han, J.-J. Chen, J.-Z. Chen*. Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor Mini-Rev. Med. Chem., 2014, 14, 426-443. 12. S. Han, F.-F. Zhang, X. Xie, J.-Z. Chen*, Design, synthesis, biological evaluation, and comparative docking study of 1,2,4-triazolones as CB1 receptor selective antagonists. Eur. J. Med. Chem., 2014, 74, 73-84 13. Y. Cao, Z.-J. Chen, H.-D. Jiang, and J.-Z. Chen*. Computational Studies of the Regioselectivities of COMT-Catalyzed Meta-/Para-O Methylations of Luteolin and Quercetin. J. Phys. Chem. B 2014, 118, 470-481 14. L. Yu, J. Pu, M. Zuo, X. Zhang, Y. Cao, S. Chen, Y. Lou, Q. Zhou H. Hu, H.Jiang, J.-Z. Chen*, S. Zeng*. Hepatic Glucuronidation of Isoneochamaejasmin A from the Traditional Chinese Medicine Stellera Chamaejasme L. Root. Drug Metab. Dispos. 2014, 42, 1–9. 15. S.-F. Chen, Y. Cao, S. Han, J.-Z. Chen*. Insight into the structural mechanism for PKB _ allosteric inhibition by molecular dynamics simulations and free energy calculations. J. Mol. Graph. Model. 48 (2014) 36–46 16. S.-F. Chen, Y. Cao. J.-J. Chen, J.-Z. Chen*. Binding selectivity studies of PKBαusing molecular dynamics simulation and free energy calculations. J. Mol. Model. 2013, 19:5097-5112, 17. S. Chen, J.-Z. Chen*, Development for anticancer therapy small-molecule inhibitors targeting protein kinase B. Mini-Rev. Med. Chem.,2013, 23:1272-1294, 18. J.-J. Chen, Shuang Han, Yang Cao, Jian-Zhong Chen*,The agonist binding mechanism of human CB2 receptor studied by molecular dnamics simulation, free energy calculation and 3D-QSAR studies, 药学学报2013，48:1436-1449， 19. L. Ou, S. Han, W. Ding, Z. Chen, Z. Ye, H. Yang, G. Zhang, Y. Lou, J.-Z. Chen*, Y. Yu*. Design, synthesis and 3D-QSAR study of cytotoxic flavonoid derivatives, Mol. Diver. 2011, 15:665–675. 20. L. Ou, S. Han, W. Ding, P. Jia, B. Yang, J. L. Medina-Franco, M. A. Giulianotti, J.-Z. Chen*, Y. Yu*, Parallel synthesis of novel antitumor agents: 1,2,3-triazoles bearing biologically active sulfonamide moiety and their 3D-QSAR. Mol. Diver. 2011, 15:927–946. 21. C. Jiang, S. Han, T. Chen, J.-Z. Chen*. 3D-QSAR and docking studies of arylmethylamine-based DPP IV inhibitors Acta Pharmaceutica Sinica B 2012, 2(4):411–420 22. J.-Z. Chen, K.-Z. Myint, X.-Q. Xie, New QSAR prediction models derived from GPCR CB2-antagonistic triaryl bis-sulfone analogues by a combined molecular morphological and pharmacophoric approach. SAR and QSAR in Environmental Research. (2011), 22(5-6): 525–544. 23. 刘瑶, 洪岚, 余露山, 蒋惠娣, 陈建忠, 孟琴, 陈枢青, 曾苏，创新药物转化研究中ADME 的评价，药学学报，2011, 46 (1): 19-29